Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center.

Abstract:

RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory epilepsy seen at a tertiary US epilepsy center. METHODS:We retrospectively reviewed the use of CLB, 1 measure of efficacy (6-month seizure freedom), 1-year retention, and tolerability in patients with epilepsy who were prescribed CLB as part of their antiepileptic drug regimen at the Columbia Comprehensive Epilepsy Center over a 5-year period. RESULTS:Two hundred fifty-one patients were prescribed CLB, of which 62 were newly started on CLB at our center during this period (29 male and 33 female subjects; mean age, 43.9 years; range, 8-88 years). Clobazam dose ranged from 5 to 60 mg/d (mean, 23.9 mg/d). The mean number of previous antiepileptic drug trials per patient was 7.7. Of the 62 patients newly started on CLB, 7 patients (11.3%) became seizure-free for at least 6 months after introduction of CLB. Binary logistic regression was unable to identify any significant predictors of seizure freedom or CLB retention. Four patients remained seizure-free on CLB for more than 18 months. The Kaplan-Meier 12-month retention curve (n = 54 eligible patients) showed a 1-year retention rate of 61%. CONCLUSIONS:In this population of patients with highly refractory epilepsy at a US center, 11% of patients became seizure-free for at least 6 months after addition of CLB, and the 1-year retention rate was 61%.

journal_name

Clin Neuropharmacol

authors

Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

doi

10.1097/WNF.0b013e31815cd960

subject

Has Abstract

pub_date

2008-11-01 00:00:00

pages

333-8

issue

6

eissn

0362-5664

issn

1537-162X

pii

00002826-200811000-00003

journal_volume

31

pub_type

杂志文章
  • Effects of terguride in patients with Huntington's disease.

    abstract::trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198910000-00008

    authors: Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

    更新日期:1989-10-01 00:00:00

  • Cytosolic and nuclear sex steroid receptors in meningioma.

    abstract::To determine the nature of the hormone dependency of meningioma, particularly whether progestin receptor (PR) and tumor growth are estrogen-dependent, we measured the cytosol estrogen receptor (ER) and PR separately by an exchange assay with [3H]R 2858 (for ER) and [3H]RU 27987 (for PR) in 21 meningiomas. We correlate...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198412000-00018

    authors: Moguilewsky M,Pertuiset BF,Verzat C,Philibert D,Philippon J,Poisson M

    更新日期:1984-01-01 00:00:00

  • Levetiracetam is not effective for essential tremor.

    abstract:OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013E31807A32C6

    authors: Elble RJ,Lyons KE,Pahwa R

    更新日期:2007-11-01 00:00:00

  • Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

    abstract:OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.wnf.0000180228.77802.32

    authors: Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

    更新日期:2005-09-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.

    abstract::A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31811510ed

    authors: Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

    更新日期:2008-05-01 00:00:00

  • Seizure control after chronic pharmacotherapy in epileptic disorders beginning after 40 years of age.

    abstract::Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199502000-00002

    authors: Hasegawa H,Kanner AM

    更新日期:1995-02-01 00:00:00

  • Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect.

    abstract::Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and ext...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000364

    authors: Schwitalla TA,Patel RA,Catalano G,Nirmalani-Gandhy A

    更新日期:2019-11-01 00:00:00

  • Severe weight gain induced by combination treatment with risperidone and paroxetine.

    abstract::Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200209000-00009

    authors: Fukui H,Murai T

    更新日期:2002-09-01 00:00:00

  • Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys.

    abstract::In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198602000-00010

    authors: Povlsen UJ,Noring U,Laursen AL,Korsgaard S,Gerlach J

    更新日期:1986-01-01 00:00:00

  • Mesulergine (CU 32-085) in the treatment of Parkinson's disease.

    abstract::The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198604000-00005

    authors: Rascol A,Montastruc JL,Rascol O,Senard JM

    更新日期:1986-01-01 00:00:00

  • A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.

    abstract::Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.WNF.0000220819.71231.96

    authors: Mauri MC,Colasanti A,Rossattini M,Moliterno D,Baldi ML,Papa P

    更新日期:2006-05-01 00:00:00

  • One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients.

    abstract:OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000255

    authors: Kim DW,Oh J

    更新日期:2018-01-01 00:00:00

  • Paroxysmal dystonia responsive to anticholinergic drugs.

    abstract::A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198708000-00007

    authors: Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

    更新日期:1987-08-01 00:00:00

  • Clinical implications of sustained dopaminergic stimulation.

    abstract::Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

    更新日期:1994-01-01 00:00:00

  • Treatment of Tourette's syndrome with calcium antagonists.

    abstract::Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199002000-00008

    authors: Micheli F,Gatto M,Lekhuniec E,Mangone C,Fernandez Pardal M,Pikielny R,Casas Parera I

    更新日期:1990-02-01 00:00:00

  • Poor tolerability of a transdermal nicotine treatment in Parkinson's disease.

    abstract::Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200309000-00004

    authors: Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

    更新日期:2003-09-01 00:00:00

  • Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.

    abstract::A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

    更新日期:1998-07-01 00:00:00

  • Prescribing Trends of Atypical Antipsychotic Drugs in an Outpatient Unit of a Child and Adolescent Clinic in Turkey.

    abstract:OBJECTIVE:Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psych...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000263

    authors: Yektaş Ç,Tufan AE

    更新日期:2018-01-01 00:00:00

  • The effects of flumazenil in neuropsychiatric disorders.

    abstract::Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199506000-00002

    authors: Malizia AL,Nutt DJ

    更新日期:1995-06-01 00:00:00

  • Serotonin syndrome after electroconvulsive therapy in a patient on trazodone, bupropion, and quetiapine: a case report.

    abstract:BACKGROUND:Serotonin syndrome is a potentially fatal complication that usually occurs in the combination use of several serotonergic agents. We presented a patient with major depressive disorder under the treatment of bupropion, trazodone, and quetiapine. Serotonin syndrome developed soon after she received the first s...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000076

    authors: Cheng YC,Liang CM,Liu HC

    更新日期:2015-05-01 00:00:00

  • The syndrome of irreversible lithium-effectuated neurotoxicity.

    abstract:OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000150871.52253.b7

    authors: Adityanjee,Munshi KR,Thampy A

    更新日期:2005-01-01 00:00:00

  • Hypothermia induced by atypical neuroleptics.

    abstract::Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred. Nine other ca...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schwaninger M,Weisbrod M,Schwab S,Schröder M,Hacke W

    更新日期:1998-11-01 00:00:00

  • Cytokine production in anorexia nervosa.

    abstract::The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199306000-00007

    authors: Bessler H,Karp L,Notti I,Apter A,Tyano S,Djaldetti M,Weizman R

    更新日期:1993-06-01 00:00:00

  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00

  • Tardive akathisia due to sulpiride.

    abstract::A 56 year-old woman who suffered from parkinsonism, oro-lingual dyskinesia (OLD) and tardive akathisia (TA) due to sulpiride is reported. OLD and TA appeared after sulpiride withdrawal. The patient was successfully treated with tetrabenazine even a mild parkinsonism was present. TA seems to be related with an apparent...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199410000-00013

    authors: López de Munain A,Poza JJ,Gorospe A,Arce A,Martí Massó JF

    更新日期:1994-10-01 00:00:00

  • Cognitive improvement in clinical trials with nootropic drugs: when can it be expected and how to clarify its meaning.

    abstract::In order to have a correct evaluation of the activity of a nootropic drug, the criteria adopted for the choice of patients to be included in the clinical trials and the methods used to clarify the meaning of changes observed on cognitive tasks are reported. The results of a clinical trial with the nootropic oxiracetam...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Gainotti G,Benedetti N,Caltagirone C,Nocentini U

    更新日期:1986-01-01 00:00:00

  • Piracetam in the treatment of different types of myoclonus.

    abstract::Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198812000-00006

    authors: Obeso JA,Artieda J,Quinn N,Rothwell JC,Luquin MR,Vaamonde J,Marsden CD

    更新日期:1988-12-01 00:00:00

  • Plasma-level response relationships with fluoxetine and zimelidine.

    abstract::The results of pharmacokinetic studies of two recent 5-HT uptake inhibitors, zimelidine and fluoxetine, have pointed to the inadequacy of open-dose rising studies for establishing the most appropriate dose of new antidepressants. High plasma concentrations of the active metabolites, norzimelidine and norfluoxetine, we...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199001001-00008

    authors: Montgomery SA,Baldwin D,Shah A,Green M,Fineberg N,Montgomery D

    更新日期:1990-01-01 00:00:00

  • A case of severe parkinsonism associated with short-term treatment with milnacipran.

    abstract::A 51-year-old woman became depressed following the death of her father-in-law. She was given 50 mg of milnacipran a day. One week after starting milnacipran, she developed parkinsonism. The milnacipran was increased to 100 mg/d, resulting in a situation where her symptoms of parkinsonism and depression worsened, which...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31815947c7

    authors: Muraoka T,Oku E,Sugataka K,Yamada S

    更新日期:2008-09-01 00:00:00